Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer offered insights on. Cramer discussed the company’s acquisition of ...

In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 (GLP-1) medications were less than ...

Wegovy, the blockbuster weight-loss drug launched in June, is set to get cheaper in India. Danish drugmaker Novo Nordisk has ...

It's impossible to avoid headlines about GLP-1 medications. The weight-loss drugs target hormones in the gut and brain that ...

So it was the government shutdown and some insane comments from OpenAI about a government backstop because of gigantic ...

Lucy D. Mastrandrea, MD, PhD, professor of pediatrics in the Jacobs School of Medicine and Biomedical Sciences, has been ...

Study also revealed no increased risk for major adverse cardiovascular events for patients on a GLP-1 RA versus those not on a GLP-1 RA.

Tirzepatide, semaglutide, and liraglutide vs DPP4i were associated with lower risk of alcohol use disorder, especially among men and younger patients.

Shares of Amgen are up nearly 26% this year and have soared 11% just over the past week.

Did people really mean it when they said being fat is fine, and they don't want to be thin? GLP-1 drugs may be changing this ...

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy and Mounjaro — were linked to improved survival among colon cancer patients in a new observational study from UC San Diego.